NPI: 1043348808 · LOUISVILLE, KY 40202 · Psychiatric Hospital Unit · NPI assigned 03/01/2007
Authorized official GAST, SHELLEY controls 20+ related entities in our dataset. Read more
| Authorized Official | GAST, SHELLEY (VP MANAGED CARE) |
| NPI Enumeration Date | 03/01/2007 |
Other providers sharing the same authorized official: GAST, SHELLEY
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 1,259,556 | $71.11M |
| 2019 | 1,244,257 | $75.93M |
| 2020 | 1,141,455 | $74.04M |
| 2021 | 1,278,407 | $106.80M |
| 2022 | 1,024,455 | $91.70M |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 99284 | Emergency department visit for the evaluation and management, high severity | 172,180 | 145,714 | $53.75M |
| 99283 | Emergency department visit for the evaluation and management, moderate severity | 181,711 | 162,844 | $40.47M |
| 99285 | Emergency department visit for the evaluation and management, high severity with immediate threat to life | 64,361 | 45,968 | $19.07M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 31,946 | 28,254 | $11.98M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 57,392 | 52,311 | $11.55M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 19,342 | 16,684 | $9.35M |
| G0378 | Hospital observation service, per hour | 52,668 | 23,231 | $8.21M |
| C1776 | Joint device (implantable) | 782 | 683 | $7.51M |
| J9271 | Injection, pembrolizumab, 1 mg | 1,347 | 808 | $7.31M |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 5,303 | 4,322 | $7.18M |
| 70450 | Computed tomography, head or brain; without contrast material | 35,783 | 30,019 | $7.11M |
| 70551 | Magnetic resonance imaging, brain; without contrast material | 11,598 | 10,516 | $5.87M |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | 10,752 | 9,778 | $5.84M |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | 10,518 | 8,487 | $5.46M |
| 96375 | Therapeutic injection; each additional sequential IV push | 74,558 | 46,152 | $4.62M |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | 1,592 | 1,311 | $4.56M |
| 78815 | Positron emission tomography (PET) for limited area imaging | 2,061 | 1,675 | $3.86M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 135,986 | 62,486 | $3.58M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 75,838 | 25,602 | $3.54M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 11,581 | 10,152 | $3.45M |
| 71275 | Computed tomographic angiography, chest, with contrast material | 10,934 | 9,633 | $3.31M |
| 77386 | 7,611 | 595 | $3.29M | |
| 72141 | 5,800 | 5,083 | $3.19M | |
| 96361 | Intravenous infusion, hydration; each additional hour | 93,860 | 49,004 | $3.18M |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 25,135 | 23,307 | $3.03M |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 9,681 | 5,145 | $2.98M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 7,735 | 6,068 | $2.82M |
| J0585 | Injection, onabotulinumtoxina, 1 unit | 6,172 | 5,324 | $2.65M |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | 8,810 | 6,365 | $2.58M |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 19,271 | 10,046 | $2.51M |
| 58661 | 1,182 | 911 | $2.40M | |
| J3490 | Unclassified drugs | 234,043 | 62,614 | $2.39M |
| 80053 | Comprehensive metabolic panel | 244,382 | 168,889 | $2.37M |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 14,392 | 13,210 | $2.36M |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 99,987 | 72,435 | $2.33M |
| 62323 | 6,270 | 4,779 | $2.29M | |
| 47562 | 1,361 | 941 | $2.20M | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | 4,518 | 3,995 | $2.20M |
| 58571 | 873 | 497 | $2.15M | |
| 93458 | 1,473 | 775 | $2.02M | |
| 72125 | Computed tomography, cervical spine; without contrast material | 8,748 | 7,484 | $2.02M |
| 76770 | 11,851 | 11,269 | $1.93M | |
| 71045 | Radiologic examination, chest; single view | 58,733 | 46,506 | $1.79M |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | 1,235 | 1,188 | $1.75M |
| 93017 | 7,795 | 6,723 | $1.74M | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | 2,168 | 2,075 | $1.71M |
| 71250 | 7,816 | 6,246 | $1.71M | |
| 44970 | 744 | 642 | $1.71M | |
| 93320 | 7,092 | 6,405 | $1.70M | |
| 71046 | Radiologic examination, chest; 2 views | 39,451 | 35,381 | $1.65M |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 67,824 | 25,800 | $1.58M |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 71,114 | 57,130 | $1.57M |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | 12,656 | 11,764 | $1.48M |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 3,131 | 2,636 | $1.46M |
| J2323 | Injection, natalizumab, 1 mg | 338 | 280 | $1.42M |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 30,682 | 19,196 | $1.38M |
| J2350 | Injection, ocrelizumab, 1 mg | 78 | 66 | $1.35M |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | 3,062 | 2,834 | $1.34M |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 248,520 | 183,140 | $1.30M |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | 6,243 | 5,522 | $1.27M |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 15,893 | 15,194 | $1.27M |
| 76830 | Ultrasound, transvaginal | 9,940 | 9,022 | $1.25M |
| 36512 | 1,578 | 1,386 | $1.20M | |
| 72131 | 4,351 | 3,654 | $1.19M | |
| 72146 | 2,295 | 2,060 | $1.16M | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | 2,346 | 2,013 | $1.14M |
| 41899 | Unlisted procedure, dentoalveolar structures | 2,200 | 1,987 | $1.13M |
| 74019 | 17,156 | 16,096 | $1.11M | |
| 36415 | Collection of venous blood by venipuncture | 286,765 | 123,111 | $1.08M |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 4,837 | 4,607 | $1.07M |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | 2,229 | 1,855 | $1.06M |
| 96376 | 18,657 | 11,278 | $1.06M | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 25,127 | 7,299 | $1.06M |
| 73221 | 2,237 | 1,965 | $1.04M | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 21,395 | 18,218 | $1.02M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 23,047 | 16,556 | $988K |
| 70496 | 2,906 | 2,390 | $953K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | 7,996 | 7,572 | $925K |
| J3380 | Injection, vedolizumab, intravenous, 1 mg | 185 | 166 | $914K |
| J2505 | Injection, pegfilgrastim, 6 mg | 282 | 174 | $908K |
| 77334 | 1,979 | 1,079 | $895K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 1,763 | 1,354 | $858K |
| 70491 | 3,166 | 2,627 | $849K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 12,466 | 9,800 | $843K |
| 70486 | 3,713 | 3,313 | $825K | |
| J0185 | Injection, aprepitant, 1 mg | 3,892 | 2,125 | $815K |
| 93975 | 6,370 | 5,919 | $808K | |
| 62321 | 2,023 | 1,650 | $803K | |
| 70498 | 2,833 | 2,467 | $800K | |
| 74018 | 13,334 | 11,930 | $800K | |
| 76536 | 6,391 | 5,966 | $797K | |
| 93971 | 7,314 | 6,593 | $790K | |
| 83880 | 39,430 | 33,980 | $785K | |
| 72158 | 1,640 | 1,395 | $781K | |
| 64615 | 6,479 | 4,890 | $775K | |
| 76642 | 8,720 | 8,093 | $770K | |
| 36561 | 874 | 552 | $753K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | 4,628 | 3,108 | $744K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 5,709 | 2,324 | $728K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 25,240 | 22,010 | $722K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 17,590 | 6,828 | $707K |
| J9312 | Injection, rituximab, 10 mg | 193 | 90 | $705K |
| 74178 | 1,445 | 1,138 | $704K | |
| 77412 | 3,548 | 369 | $704K | |
| C1769 | Guide wire | 8,049 | 6,611 | $684K |
| 64721 | 970 | 800 | $663K | |
| 54161 | 1,219 | 1,182 | $655K | |
| 20680 | 695 | 603 | $629K | |
| 96367 | 11,764 | 4,763 | $624K | |
| 95713 | 2,282 | 1,385 | $609K | |
| 74183 | 1,233 | 992 | $606K | |
| 70544 | 1,704 | 1,363 | $590K | |
| Q5118 | Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg | 329 | 117 | $586K |
| 93325 | 8,727 | 8,055 | $583K | |
| 96415 | 4,387 | 3,250 | $580K | |
| 93970 | 4,050 | 3,617 | $575K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 12,189 | 6,599 | $574K |
| 72156 | 1,123 | 946 | $571K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | 14,784 | 12,959 | $570K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | 3,258 | 3,021 | $562K |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | 2,375 | 1,856 | $555K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 29,525 | 25,564 | $547K |
| 95811 | 1,281 | 1,151 | $545K | |
| 84484 | 70,752 | 45,414 | $541K | |
| 72197 | 1,017 | 816 | $534K | |
| 54300 | 512 | 494 | $532K | |
| J0897 | Injection, denosumab, 1 mg | 544 | 395 | $512K |
| 73630 | 11,289 | 9,647 | $512K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | 6,555 | 5,775 | $505K |
| 96417 | 4,617 | 2,623 | $505K | |
| 59025 | Fetal non-stress test | 13,190 | 10,426 | $497K |
| 76801 | 6,915 | 6,032 | $493K | |
| 77066 | Tomosynthesis, mammo | 4,420 | 4,028 | $484K |
| C1781 | Mesh (implantable) | 914 | 839 | $480K |
| Q5111 | Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg | 215 | 124 | $436K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 13,739 | 12,408 | $434K |
| 78227 | 1,213 | 960 | $432K | |
| 67311 | 391 | 352 | $429K | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 3,818 | 2,414 | $424K |
| 19083 | 831 | 664 | $422K | |
| 58558 | 486 | 393 | $413K | |
| 95782 | 697 | 651 | $412K | |
| 77300 | 1,595 | 959 | $411K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 9,330 | 3,724 | $406K |
| J2469 | Injection, palonosetron hcl, 25 mcg | 4,861 | 2,690 | $402K |
| 77336 | 4,481 | 1,582 | $400K | |
| 36430 | 3,310 | 1,818 | $397K | |
| J9306 | Injection, pertuzumab, 1 mg | 82 | 65 | $391K |
| 78264 | 1,688 | 1,272 | $370K | |
| 76870 | 3,241 | 2,959 | $367K | |
| 43235 | 1,151 | 796 | $362K | |
| 51600 | 2,737 | 2,623 | $362K | |
| 99213 | Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 17,044 | 12,214 | $361K |
| 73610 | 9,684 | 8,406 | $358K | |
| 93225 | 3,899 | 3,316 | $355K | |
| 73562 | 9,067 | 6,853 | $352K | |
| 36593 | 2,188 | 1,779 | $347K | |
| 52332 | 667 | 425 | $341K | |
| 74455 | 3,050 | 2,879 | $340K | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | 15,065 | 13,373 | $338K |
| J1756 | Injection, iron sucrose, 1 mg | 6,000 | 2,689 | $334K |
| C1874 | Stent, coated/covered, with delivery system | 151 | 134 | $333K |
| 73030 | 8,036 | 6,094 | $332K | |
| 72157 | 611 | 532 | $328K | |
| 64642 | 1,046 | 752 | $327K | |
| 77290 | 2,387 | 796 | $324K | |
| J9299 | Injection, nivolumab, 1 mg | 88 | 38 | $321K |
| 64643 | 902 | 713 | $321K | |
| 77065 | Tomosynthesis, mammo | 4,397 | 3,743 | $318K |
| J2785 | Injection, regadenoson, 0.1 mg | 4,685 | 4,047 | $318K |
| 64493 | 649 | 507 | $315K | |
| 73130 | 8,889 | 7,373 | $310K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | 7,378 | 2,776 | $309K |
| 80048 | Basic metabolic panel (calcium, ionized) | 44,052 | 31,856 | $307K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 23,467 | 19,499 | $307K |
| J9310 | Injection, rituximab, 100 mg | 94 | 41 | $303K |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 741 | 445 | $301K |
| 93798 | 9,740 | 1,504 | $301K | |
| C1762 | Connective tissue, human (includes fascia lata) | 85 | 79 | $297K |
| 78492 | 288 | 130 | $296K | |
| 95951 | 1,611 | 1,046 | $295K | |
| 95812 | 1,127 | 1,091 | $294K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 5,189 | 4,513 | $291K |
| 93351 | 733 | 645 | $290K | |
| 77295 | 293 | 223 | $290K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 4,541 | 3,827 | $286K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 17,230 | 16,102 | $284K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 17,442 | 16,112 | $284K |
| 95816 | 1,832 | 1,729 | $284K | |
| 72128 | 1,309 | 1,116 | $281K | |
| G0382 | Level 3 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | 1,704 | 1,617 | $281K |
| 72132 | 1,350 | 846 | $277K | |
| 84443 | Thyroid stimulating hormone (TSH) | 19,097 | 16,952 | $273K |
| 86920 | 4,936 | 2,936 | $268K | |
| G0260 | Injection procedure for sacroiliac joint; provision of anesthetic, steroid and/or other therapeutic agent, with or without arthrography | 938 | 724 | $267K |
| 51728 | 1,419 | 1,374 | $265K | |
| 95700 | 2,237 | 2,043 | $259K | |
| J1459 | Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg | 224 | 108 | $258K |
| 88341 | 2,451 | 1,852 | $256K | |
| 72110 | 5,108 | 4,320 | $255K | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 2,614 | 2,181 | $254K |
| 95716 | 850 | 687 | $251K | |
| 95886 | 1,770 | 1,622 | $247K | |
| 93922 | 2,389 | 1,865 | $246K | |
| 95813 | 1,189 | 1,079 | $245K | |
| 78431 | 212 | 176 | $243K | |
| C1788 | Port, indwelling (implantable) | 679 | 598 | $242K |
| 83735 | 46,813 | 34,861 | $239K | |
| 88342 | 6,005 | 5,104 | $239K | |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 549 | 429 | $235K |
| 74230 | 2,164 | 1,855 | $232K | |
| J1439 | Injection, ferric carboxymaltose, 1 mg | 418 | 244 | $232K |
| 96411 | 2,715 | 1,663 | $231K | |
| 77080 | 4,000 | 3,257 | $229K | |
| 95819 | 1,397 | 1,289 | $227K | |
| 73090 | 6,436 | 5,677 | $226K | |
| 50590 | 116 | 83 | $226K | |
| 86850 | 30,007 | 23,129 | $224K | |
| 78306 | 1,159 | 659 | $224K | |
| 73590 | 6,133 | 5,093 | $219K | |
| 73110 | 6,283 | 5,339 | $216K | |
| 72100 | 4,588 | 3,907 | $216K | |
| J9022 | Injection, atezolizumab, 10 mg | 53 | 25 | $216K |
| 97161 | 7,614 | 4,019 | $215K | |
| 93880 | 2,030 | 1,619 | $213K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | 1,348 | 1,275 | $208K |
| 76885 | 1,710 | 1,621 | $205K | |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | 1,493 | 1,327 | $205K |
| 88185 | 839 | 581 | $202K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 15,723 | 14,533 | $200K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 7,919 | 6,863 | $200K |
| 82728 | 15,539 | 12,822 | $198K | |
| C2617 | Stent, non-coronary, temporary, without delivery system | 1,413 | 1,205 | $196K |
| 84703 | 47,640 | 42,118 | $194K | |
| 81025 | 44,551 | 40,269 | $193K | |
| 54163 | 239 | 216 | $193K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 12,341 | 11,554 | $191K |
| 83690 | 51,759 | 44,945 | $189K | |
| J2704 | Injection, propofol, 10 mg | 65,379 | 50,086 | $188K |
| 88307 | 2,312 | 1,862 | $188K | |
| 22551 | 51 | 39 | $187K | |
| 12011 | 3,738 | 3,441 | $186K | |
| 72040 | 3,871 | 3,333 | $183K | |
| 76882 | 1,942 | 1,787 | $182K | |
| J2997 | Injection, alteplase recombinant, 1 mg | 4,075 | 1,981 | $180K |
| 77062 | 4,024 | 3,349 | $178K | |
| 81229 | 241 | 217 | $178K | |
| 86900 | 33,444 | 25,428 | $177K | |
| 29881 | 131 | 125 | $175K | |
| 10060 | 2,731 | 2,418 | $169K | |
| C1760 | Closure device, vascular (implantable/insertable) | 962 | 788 | $168K |
| 94060 | 1,674 | 1,304 | $165K | |
| 74240 | 1,484 | 1,374 | $164K | |
| 27447 | 201 | 42 | $161K | |
| 97162 | 4,737 | 2,644 | $160K | |
| Q5103 | Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg | 85 | 63 | $158K |
| 80061 | Lipid panel | 12,380 | 8,167 | $158K |
| A4648 | Tissue marker, implantable, any type, each | 1,678 | 1,282 | $156K |
| 76819 | Fetal biophysical profile; without non-stress testing | 2,197 | 1,845 | $156K |
| 75574 | 402 | 341 | $155K | |
| 12001 | 3,252 | 2,994 | $154K | |
| 76825 | 873 | 767 | $153K | |
| 77072 | 2,476 | 2,384 | $152K | |
| 94726 | 1,932 | 1,769 | $151K | |
| 86902 | 3,155 | 1,801 | $148K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 38,012 | 34,757 | $147K |
| 93226 | 3,517 | 3,218 | $147K | |
| 73560 | 3,794 | 3,247 | $146K | |
| 97535 | Self-care/home management training, each 15 minutes | 8,530 | 5,266 | $144K |
| 73700 | 681 | 579 | $144K | |
| J9202 | Goserelin acetate implant, per 3.6 mg | 320 | 283 | $143K |
| 73070 | 4,619 | 3,958 | $142K | |
| 74174 | 319 | 224 | $142K | |
| 85730 | 37,971 | 32,340 | $142K | |
| 92611 | 1,857 | 1,710 | $140K | |
| 29580 | 3,797 | 1,214 | $138K | |
| 81001 | 82,416 | 72,005 | $136K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 8,134 | 7,625 | $136K |
| 49083 | 555 | 173 | $135K | |
| A9555 | Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 821 | 417 | $135K |
| 76800 | 926 | 901 | $134K | |
| 77061 | 3,550 | 2,873 | $134K | |
| 82565 | 11,257 | 6,777 | $134K | |
| 51784 | 1,464 | 1,383 | $133K | |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | 8,698 | 7,948 | $132K |
| 77002 | 1,700 | 1,223 | $131K | |
| 99157 | 2,467 | 2,321 | $130K | |
| 73502 | 3,601 | 2,814 | $130K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 5,248 | 4,801 | $130K |
| 73521 | 2,181 | 2,039 | $128K | |
| 94010 | 3,033 | 2,390 | $125K | |
| 54640 | 96 | 86 | $125K | |
| Q5107 | Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg | 97 | 38 | $124K |
| 85027 | 31,670 | 26,658 | $124K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 4,914 | 1,934 | $123K |
| 85610 | 46,352 | 37,678 | $123K | |
| 97116 | 6,219 | 2,939 | $123K | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 3,071 | 2,634 | $122K |
| 95910 | 847 | 697 | $121K | |
| C1726 | Catheter, balloon dilatation, non-vascular | 783 | 647 | $121K |
| 20936 | 317 | 221 | $121K | |
| 20930 | 234 | 178 | $121K | |
| 62304 | 230 | 195 | $119K | |
| J1453 | Injection, fosaprepitant, 1 mg | 518 | 302 | $113K |
| 86003 | 1,464 | 1,207 | $112K | |
| 87486 | 5,201 | 4,869 | $110K | |
| 96409 | 1,218 | 760 | $110K | |
| 72082 | 1,119 | 1,049 | $110K | |
| 73552 | 2,804 | 2,353 | $106K | |
| 86922 | 1,505 | 796 | $106K | |
| 84439 | 10,967 | 9,858 | $106K | |
| 96416 | 730 | 401 | $105K | |
| 87581 | 5,188 | 4,878 | $105K | |
| 72072 | 2,670 | 2,208 | $103K | |
| 55175 | 407 | 390 | $103K | |
| 84702 | 11,588 | 9,707 | $100K | |
| 76937 | 1,530 | 1,261 | $99K | |
| 88304 | 4,560 | 4,053 | $99K | |
| 96402 | 1,552 | 1,238 | $98K | |
| 73060 | 2,925 | 2,530 | $97K | |
| 29581 | 2,443 | 685 | $97K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 49,710 | 23,445 | $96K |
| 95806 | 1,075 | 994 | $95K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 5,439 | 5,145 | $94K |
| Q9950 | Injection, sulfur hexafluoride lipid microspheres, per ml | 2,856 | 1,863 | $91K |
| 77075 | 632 | 602 | $91K | |
| C8908 | Magnetic resonance imaging without contrast followed by with contrast, breast; bilateral | 188 | 138 | $90K |
| 64644 | 306 | 194 | $89K | |
| J9035 | Injection, bevacizumab, 10 mg | 25 | 12 | $88K |
| 86901 | 31,001 | 25,226 | $88K | |
| 70480 | 308 | 287 | $88K | |
| 83036 | Hemoglobin; glycosylated (A1C) | 10,466 | 9,057 | $88K |
| J9355 | Injection, trastuzumab, excludes biosimilar, 10 mg | 32 | 12 | $87K |
| 93308 | 576 | 401 | $86K | |
| 87040 | 15,977 | 10,447 | $86K | |
| 92526 | 1,550 | 814 | $86K | |
| 88360 | 581 | 455 | $86K | |
| 77001 | 1,119 | 916 | $85K | |
| 43762 | 634 | 549 | $82K | |
| 12002 | 1,421 | 1,300 | $82K | |
| 83540 | 11,143 | 10,107 | $81K | |
| 49585 | 90 | 88 | $79K | |
| 82784 | 5,513 | 3,776 | $78K | |
| 73222 | 185 | 166 | $78K | |
| 84112 | 1,940 | 1,726 | $78K | |
| 73140 | 2,842 | 2,533 | $77K | |
| 87522 | Neg quan hep c or qual rna | 2,219 | 2,046 | $77K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 3,890 | 3,137 | $77K |
| 70487 | 296 | 266 | $77K | |
| 96368 | 4,028 | 745 | $77K | |
| 82607 | 5,745 | 4,477 | $76K | |
| 76942 | 857 | 733 | $76K | |
| 73200 | 239 | 205 | $74K | |
| 10005 | 207 | 171 | $74K | |
| 71271 | 1,941 | 1,629 | $74K | |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | 1,067 | 799 | $74K |
| 51797 | 961 | 932 | $73K | |
| 83605 | 10,123 | 8,030 | $73K | |
| 94729 | 1,692 | 1,554 | $73K | |
| 87070 | 19,251 | 17,085 | $72K | |
| 86945 | 2,466 | 1,023 | $70K | |
| 58563 | 27 | 27 | $69K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 21,944 | 20,755 | $67K |
| 42830 | 79 | 73 | $67K | |
| 76000 | 757 | 707 | $67K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | 719 | 661 | $67K |
| 80074 | 2,070 | 1,902 | $66K | |
| 97750 | 2,715 | 1,992 | $65K | |
| 72050 | 1,448 | 1,158 | $65K | |
| J9070 | Cyclophosphamide, 100 mg | 300 | 101 | $62K |
| 71101 | 1,974 | 1,452 | $62K | |
| 70470 | 165 | 122 | $62K | |
| Q5115 | Injection, rituximab-abbs, biosimilar, (truxima), 10 mg | 27 | 14 | $61K |
| 86140 | 17,813 | 15,065 | $61K | |
| 29105 | 1,019 | 954 | $61K | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 4,678 | 1,416 | $61K |
| 29125 | 1,622 | 1,503 | $61K | |
| 85007 | 26,304 | 22,687 | $60K | |
| 81003 | 45,356 | 41,056 | $60K | |
| Q5117 | Injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg | 22 | 13 | $60K |
| 58300 | 148 | 130 | $60K | |
| 59820 | 57 | 51 | $59K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 18,400 | 12,856 | $59K |
| C9463 | Injection, aprepitant, 1 mg | 253 | 143 | $59K |
| J9173 | Injection, durvalumab, 10 mg | 57 | 13 | $59K |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | 34,217 | 13,982 | $59K |
| 83021 | 4,340 | 2,678 | $59K | |
| 94762 | 1,833 | 1,285 | $59K | |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | 128 | 106 | $58K |
| C1889 | Implantable/insertable device, not otherwise classified | 31 | 26 | $58K |
| 29826 | 107 | 97 | $58K | |
| 90715 | 4,455 | 4,113 | $58K | |
| 29827 | 50 | 43 | $57K | |
| J3489 | Injection, zoledronic acid, 1 mg | 740 | 611 | $57K |
| 83516 | 2,118 | 1,764 | $56K | |
| 82803 | 3,944 | 3,195 | $56K | |
| 70250 | 941 | 804 | $55K | |
| J0690 | Injection, cefazolin sodium, 500 mg | 28,232 | 20,542 | $55K |
| 99214 | Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 2,530 | 2,085 | $54K |
| 62270 | 322 | 267 | $53K | |
| 64635 | 65 | 50 | $53K | |
| 80069 | 8,431 | 6,843 | $52K | |
| 76827 | 783 | 729 | $52K | |
| 91200 | 770 | 734 | $52K | |
| J9045 | Injection, carboplatin, 50 mg | 2,206 | 1,212 | $51K |
| 92610 | 756 | 631 | $51K | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 9,526 | 7,551 | $50K |
| 72170 | 1,594 | 1,312 | $50K | |
| 25605 | 161 | 143 | $50K | |
| 97168 | 1,350 | 1,262 | $50K | |
| 88313 | 982 | 761 | $49K | |
| 82150 | 14,109 | 12,735 | $48K | |
| 70360 | 1,571 | 1,468 | $47K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | 31,446 | 24,979 | $47K |
| 87077 | 11,134 | 9,676 | $47K | |
| 94660 | 791 | 554 | $47K | |
| 36600 | 3,526 | 3,081 | $47K | |
| 85379 | 10,258 | 9,368 | $47K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 9,569 | 7,120 | $46K |
| Q0222 | Injection, bebtelovimab, 175 mg | 187 | 132 | $46K |
| 99155 | 1,976 | 1,840 | $46K | |
| Q9958 | High osmolar contrast material, up to 149 mg/ml iodine concentration, per ml | 3,255 | 3,164 | $46K |
| 36902 | 63 | 27 | $45K | |
| 72081 | 595 | 571 | $45K | |
| 87902 | 284 | 273 | $45K | |
| 51741 | 764 | 722 | $45K | |
| 97164 | 1,244 | 1,160 | $45K | |
| 84100 | 11,565 | 8,152 | $44K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 12,158 | 10,158 | $43K |
| 94760 | 3,843 | 2,540 | $43K | |
| 72020 | 819 | 699 | $43K | |
| 96450 | 248 | 197 | $43K | |
| 77076 | 603 | 530 | $42K | |
| 64494 | 526 | 443 | $42K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 65,999 | 48,657 | $42K |
| C1729 | Catheter, drainage | 1,504 | 764 | $42K |
| 97166 | 1,289 | 844 | $42K | |
| 99153 | Mod sedat endo service >5yrs | 959 | 818 | $41K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 55,552 | 46,132 | $41K |
| 54304 | 44 | 44 | $41K | |
| 82330 | 3,749 | 2,926 | $40K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | 843 | 791 | $40K |
| 94664 | 8,625 | 6,319 | $39K | |
| 78708 | 189 | 159 | $39K | |
| 96523 | 1,823 | 1,304 | $39K | |
| 77280 | 713 | 228 | $39K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 82,422 | 64,132 | $38K |
| 27130 | 15 | 12 | $38K | |
| 94644 | 2,901 | 2,735 | $38K | |
| 73000 | 1,180 | 1,066 | $38K | |
| 86923 | 2,002 | 999 | $38K | |
| 73080 | 1,264 | 1,004 | $37K | |
| 87186 | 9,096 | 8,120 | $36K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 57,161 | 40,052 | $36K |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 4,105 | 2,770 | $36K |
| J3370 | Injection, vancomycin hcl, 500 mg | 6,122 | 3,330 | $36K |
| 72070 | 889 | 730 | $36K | |
| 82550 | 6,528 | 5,274 | $36K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | 1,988 | 1,171 | $36K |
| 88348 | 107 | 103 | $35K | |
| 84145 | 2,396 | 2,112 | $35K | |
| 72195 | 70 | 64 | $35K | |
| 74270 | 241 | 223 | $35K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | 9,448 | 7,803 | $34K |
| 64483 | 72 | 64 | $34K | |
| J0640 | Injection, leucovorin calcium, per 50 mg | 1,314 | 436 | $33K |
| 93976 | 398 | 371 | $33K | |
| J1170 | Injection, hydromorphone, up to 4 mg | 24,080 | 15,993 | $33K |
| 36591 | 1,578 | 1,199 | $33K | |
| J9267 | Injection, paclitaxel, 1 mg | 1,427 | 615 | $33K |
| 93926 | 359 | 291 | $32K | |
| 86665 | 3,162 | 2,087 | $31K | |
| 87205 | 14,420 | 12,970 | $31K | |
| 73620 | 1,034 | 879 | $31K | |
| 82378 | 1,686 | 1,375 | $31K | |
| 82746 | 2,444 | 2,193 | $31K | |
| 75565 | 97 | 90 | $31K | |
| 83970 | 927 | 750 | $30K | |
| 85652 | 13,223 | 11,210 | $30K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 7,736 | 6,658 | $30K |
| 83615 | 4,697 | 3,978 | $29K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 57,348 | 45,797 | $29K |
| 99152 | 1,137 | 936 | $29K | |
| 23350 | 252 | 234 | $29K | |
| 93321 | 311 | 288 | $29K | |
| 80197 | 1,967 | 1,086 | $29K | |
| G0381 | Level 2 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | 297 | 289 | $28K |
| A9537 | Technetium tc-99m mebrofenin, diagnostic, per study dose, up to 15 millicuries | 985 | 921 | $28K |
| 97167 | 727 | 516 | $28K | |
| 95874 | 383 | 347 | $28K | |
| 14040 | 98 | 97 | $28K | |
| 85576 | 766 | 560 | $27K | |
| 85045 | 9,130 | 6,143 | $27K | |
| J0878 | Injection, daptomycin, 1 mg | 98 | 14 | $27K |
| 87400 | 8,325 | 4,027 | $27K | |
| 77301 | 19 | 13 | $27K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | 9,456 | 4,442 | $27K |
| 97165 | 656 | 493 | $27K | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 4,919 | 4,044 | $26K |
| 76376 | 303 | 288 | $26K | |
| P9041 | Infusion, albumin (human), 5%, 50 ml | 1,149 | 965 | $25K |
| 22853 | 78 | 66 | $25K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 7,295 | 6,671 | $25K |
| 87634 | 804 | 779 | $25K | |
| 86780 | 3,008 | 2,673 | $25K | |
| 87210 | 14,038 | 10,010 | $25K | |
| 88184 | 731 | 597 | $25K | |
| 86664 | 2,332 | 2,080 | $25K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | 287 | 254 | $25K |
| A9585 | Injection, gadobutrol, 0.1 ml | 1,029 | 794 | $25K |
| G0257 | Unscheduled or emergency dialysis treatment for an esrd patient in a hospital outpatient department that is not certified as an esrd facility | 128 | 74 | $25K |
| 24640 | 304 | 292 | $24K | |
| 95911 | 126 | 99 | $24K | |
| 82785 | 1,339 | 1,268 | $24K | |
| 83883 | 2,018 | 1,021 | $24K | |
| 70543 | 44 | 42 | $24K | |
| 90375 | 17 | 12 | $24K | |
| 73660 | 966 | 833 | $24K | |
| 96401 | 355 | 157 | $24K | |
| 77470 | 47 | 40 | $23K | |
| A9541 | Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries | 1,433 | 1,306 | $23K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 7,478 | 3,819 | $23K |
| Q9957 | Injection, perflutren lipid microspheres, per ml | 350 | 236 | $22K |
| J9190 | Injection, fluorouracil, 500 mg | 3,009 | 665 | $22K |
| C1758 | Catheter, ureteral | 1,726 | 1,195 | $22K |
| 74160 | 74 | 49 | $22K | |
| 62328 | 69 | 54 | $22K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 12,929 | 6,608 | $22K |
| 82947 | 3,808 | 2,905 | $22K | |
| 84132 | 6,151 | 4,967 | $21K | |
| 72126 | 126 | 68 | $21K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 26,347 | 22,154 | $21K |
| 58662 | 14 | 13 | $21K | |
| 86334 | 1,280 | 1,096 | $21K | |
| 86038 | 1,867 | 1,700 | $20K | |
| 29515 | 522 | 479 | $20K | |
| 43245 | 26 | 26 | $20K | |
| 86870 | 404 | 313 | $20K | |
| 70260 | 178 | 162 | $20K | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 9,707 | 7,316 | $19K |
| J2270 | Injection, morphine sulfate, up to 10 mg | 21,286 | 17,077 | $19K |
| 86304 | 1,142 | 849 | $19K | |
| 11043 | 65 | 38 | $19K | |
| 77012 | 105 | 97 | $19K | |
| 88302 | 1,106 | 940 | $18K | |
| 87075 | 2,274 | 1,928 | $18K | |
| 90686 | 2,504 | 2,399 | $18K | |
| 86328 | 434 | 333 | $18K | |
| 92585 | 167 | 149 | $17K | |
| 31624 | 26 | 26 | $17K | |
| 88108 | 699 | 587 | $17K | |
| 84403 | 752 | 683 | $17K | |
| 88312 | 571 | 425 | $17K | |
| 95885 | 244 | 233 | $17K | |
| J1626 | Injection, granisetron hydrochloride, 100 mcg | 3,084 | 1,276 | $17K |
| A9562 | Technetium tc-99m mertiatide, diagnostic, per study dose, up to 15 millicuries | 304 | 290 | $17K |
| 94621 | 58 | 44 | $17K | |
| 74022 | 436 | 400 | $17K | |
| 73718 | 47 | 38 | $16K | |
| 86803 | 1,724 | 1,562 | $16K | |
| 85660 | 2,582 | 1,697 | $16K | |
| 87340 | 2,521 | 2,248 | $16K | |
| J2805 | Injection, sincalide, 5 micrograms | 286 | 265 | $16K |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | 4,465 | 1,029 | $16K |
| 82533 | 1,081 | 837 | $16K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 18,435 | 13,443 | $16K |
| 64636 | 48 | 37 | $16K | |
| 86301 | 622 | 500 | $16K | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 3,378 | 2,488 | $16K |
| 43760 | 178 | 154 | $16K | |
| A9503 | Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | 850 | 754 | $16K |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 3,904 | 3,453 | $16K |
| 99156 | 974 | 896 | $15K | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 4,350 | 1,546 | $15K |
| 86663 | 2,203 | 2,079 | $15K | |
| 86706 | 1,997 | 1,845 | $15K | |
| 36590 | 53 | 43 | $15K | |
| 43249 | 46 | 25 | $15K | |
| 84238 | 540 | 494 | $15K | |
| G0008 | Administration of influenza virus vaccine | 308 | 227 | $14K |
| C9113 | Injection, pantoprazole sodium, per vial | 7,442 | 4,949 | $14K |
| 85240 | 966 | 876 | $14K | |
| 87046 | 2,405 | 1,496 | $14K | |
| 81002 | 2,645 | 2,287 | $14K | |
| 94645 | 687 | 640 | $14K | |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | 1,155 | 809 | $13K |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | 701 | 631 | $13K |
| 90688 | 2,537 | 2,358 | $13K | |
| 82105 | 864 | 700 | $13K | |
| 53020 | 12 | 12 | $13K | |
| 80164 | 1,263 | 1,091 | $13K | |
| 38222 | 45 | 42 | $13K | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | 3,257 | 2,815 | $13K |
| 72083 | 117 | 110 | $13K | |
| 87529 | 628 | 418 | $13K | |
| 73564 | 411 | 348 | $13K | |
| 36416 | 3,769 | 2,864 | $12K | |
| 86704 | 1,036 | 948 | $12K | |
| 84165 | 1,438 | 1,241 | $12K | |
| 83520 | 933 | 832 | $12K | |
| 86147 | 355 | 243 | $12K | |
| 85384 | 1,635 | 1,318 | $12K | |
| 84481 | 873 | 811 | $12K | |
| 87799 | 387 | 268 | $12K | |
| 83921 | 662 | 612 | $11K | |
| 64718 | 13 | 12 | $11K | |
| J7298 | Levonorgestrel-releasing intrauterine contraceptive system (mirena), 52 mg | 15 | 13 | $11K |
| 20610 | 88 | 75 | $11K | |
| 83655 | 943 | 871 | $11K | |
| 85014 | 5,766 | 4,528 | $11K | |
| 78582 | 71 | 60 | $11K | |
| 84156 | 2,554 | 2,110 | $11K | |
| J0248 | Injection, remdesivir, 1 mg | 76 | 32 | $11K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 3,239 | 3,049 | $11K |
| 82570 | 2,548 | 2,187 | $11K | |
| J9263 | Injection, oxaliplatin, 0.5 mg | 363 | 87 | $10K |
| 84460 | 2,150 | 1,922 | $10K | |
| 83001 | 694 | 639 | $10K | |
| 80076 | 1,360 | 1,109 | $10K | |
| 86800 | 711 | 655 | $10K | |
| C2628 | Catheter, occlusion | 98 | 91 | $10K |
| 87088 | 2,920 | 2,714 | $10K | |
| 84146 | 623 | 586 | $10K | |
| 82248 | 2,327 | 1,680 | $10K | |
| 76506 | 72 | 69 | $10K | |
| J9370 | Vincristine sulfate, 1 mg | 1,689 | 1,078 | $10K |
| 95909 | 112 | 82 | $10K | |
| 84550 | 2,557 | 2,151 | $10K | |
| 86008 | 127 | 118 | $10K | |
| J1610 | Injection, glucagon hydrochloride, per 1 mg | 122 | 106 | $10K |
| 84153 | 406 | 324 | $10K | |
| 82247 | 2,174 | 1,492 | $10K | |
| 82140 | 762 | 638 | $9K | |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | 10,454 | 7,776 | $9K |
| 92523 | 100 | 92 | $9K | |
| 77399 | 114 | 97 | $9K | |
| 76857 | 99 | 88 | $9K | |
| 88182 | 204 | 175 | $9K | |
| P9035 | Platelets, pheresis, leukocytes reduced, each unit | 22 | 12 | $9K |
| 73720 | 16 | 13 | $9K | |
| 88173 | 339 | 281 | $9K | |
| 93312 | 28 | 24 | $9K | |
| 87045 | 1,643 | 1,542 | $9K | |
| 22845 | 44 | 38 | $9K | |
| 87427 | 1,468 | 1,388 | $9K | |
| 84295 | 2,831 | 2,414 | $9K | |
| M0222 | Intravenous injection, bebtelovimab, includes injection and post administration monitoring | 93 | 88 | $9K |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | 5,802 | 4,366 | $9K |
| J3475 | Injection, magnesium sulfate, per 500 mg | 7,110 | 4,653 | $9K |
| 85597 | 599 | 483 | $8K | |
| 12013 | 149 | 133 | $8K | |
| 29505 | 140 | 131 | $8K | |
| 85018 | 4,580 | 3,489 | $8K | |
| 74328 | 71 | 68 | $8K | |
| 75561 | 18 | 15 | $8K | |
| 89051 | 1,793 | 1,553 | $8K | |
| 93923 | 68 | 59 | $8K | |
| 72220 | 225 | 205 | $7K | |
| J3480 | Injection, potassium chloride, per 2 meq | 4,516 | 2,345 | $7K |
| G0383 | Level 4 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | 36 | 35 | $7K |
| 82668 | 298 | 247 | $7K | |
| 87081 | 1,174 | 1,027 | $7K | |
| 77338 | 33 | 25 | $7K | |
| J1644 | Injection, heparin sodium, per 1000 units | 5,770 | 3,530 | $7K |
| 88377 | 53 | 43 | $7K | |
| 83525 | 518 | 487 | $7K | |
| 86146 | 299 | 190 | $7K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | 131 | 125 | $7K |
| 82270 | 2,467 | 1,908 | $6K | |
| 81243 | 141 | 130 | $6K | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | 325 | 130 | $6K |
| 70490 | 30 | 21 | $6K | |
| J2310 | Injection, naloxone hydrochloride, per 1 mg | 967 | 723 | $6K |
| 82977 | 1,030 | 819 | $6K | |
| 84305 | 328 | 311 | $6K | |
| 96377 | 134 | 83 | $6K | |
| 86769 | 332 | 310 | $6K | |
| 10022 | 45 | 40 | $6K | |
| 86480 | 124 | 114 | $6K | |
| 82945 | 1,201 | 1,024 | $6K | |
| J1953 | Injection, levetiracetam, 10 mg | 2,223 | 1,531 | $6K |
| 84157 | 1,267 | 1,106 | $6K | |
| 36569 | 14 | 12 | $6K | |
| 84436 | 971 | 879 | $6K | |
| 54360 | 34 | 33 | $6K | |
| 86308 | 2,432 | 2,303 | $6K | |
| 97014 | 386 | 140 | $5K | |
| 90675 | 20 | 12 | $5K | |
| 85397 | 209 | 202 | $5K | |
| 73723 | 18 | 12 | $5K | |
| 95711 | 82 | 81 | $5K | |
| 27096 | 18 | 16 | $5K | |
| 83010 | 537 | 472 | $5K | |
| 90732 | 253 | 219 | $5K | |
| 87483 | 39 | 36 | $5K | |
| J9201 | Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 203 | 51 | $5K |
| 86481 | 58 | 53 | $5K | |
| 85347 | 950 | 804 | $5K | |
| 83002 | 320 | 285 | $5K | |
| 82435 | 1,889 | 1,520 | $5K | |
| 84480 | 472 | 424 | $5K | |
| J9206 | Injection, irinotecan, 20 mg | 275 | 67 | $5K |
| 72192 | 15 | 15 | $5K | |
| 82010 | 1,197 | 1,032 | $5K | |
| 77049 | 15 | 13 | $5K | |
| 52000 | 14 | 14 | $5K | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | 1,871 | 846 | $4K |
| Q3014 | Telehealth originating site facility fee | 336 | 274 | $4K |
| 99215 | Prolong outpt/office vis | 205 | 162 | $4K |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 1,797 | 1,288 | $4K |
| 70481 | 31 | 25 | $4K | |
| 86703 | 711 | 665 | $4K | |
| 95912 | 13 | 13 | $4K | |
| J1956 | Injection, levofloxacin, 250 mg | 1,685 | 1,249 | $4K |
| J3411 | Injection, thiamine hcl, 100 mg | 2,453 | 1,815 | $4K |
| 73100 | 174 | 149 | $4K | |
| 85246 | 201 | 193 | $4K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 6,082 | 4,810 | $4K |
| 92587 | 77 | 71 | $4K | |
| 85613 | 492 | 469 | $4K | |
| 85612 | 291 | 282 | $4K | |
| 95908 | 52 | 43 | $4K | |
| 86708 | 367 | 346 | $4K | |
| 85245 | 201 | 191 | $3K | |
| 86431 | 684 | 643 | $3K | |
| 94618 | 147 | 133 | $3K | |
| 49452 | 13 | 13 | $3K | |
| 80177 | 298 | 272 | $3K | |
| J2060 | Injection, lorazepam, 2 mg | 5,891 | 4,494 | $3K |
| C1730 | Catheter, electrophysiology, diagnostic, other than 3d mapping (19 or fewer electrodes) | 15 | 12 | $3K |
| 87102 | 417 | 360 | $3K | |
| J0456 | Injection, azithromycin, 500 mg | 1,420 | 904 | $3K |
| 86160 | 223 | 152 | $3K | |
| J0461 | Injection, atropine sulfate, 0.01 mg | 1,030 | 704 | $3K |
| J0694 | Injection, cefoxitin sodium, 1 gm | 769 | 528 | $3K |
| 82310 | 517 | 400 | $3K | |
| 83003 | 50 | 37 | $3K | |
| 84450 | 406 | 339 | $3K | |
| 85244 | 182 | 170 | $3K | |
| 82670 | 132 | 107 | $3K | |
| 77003 | 45 | 41 | $3K | |
| 69209 | 51 | 50 | $3K | |
| 75625 | 15 | 14 | $3K | |
| 88112 | 137 | 115 | $3K | |
| 87420 | 863 | 828 | $3K | |
| 90632 | 156 | 149 | $2K | |
| J9000 | Injection, doxorubicin hydrochloride, 10 mg | 133 | 74 | $2K |
| 86376 | 235 | 227 | $2K | |
| 75710 | 14 | 13 | $2K | |
| M0239 | Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring | 24 | 16 | $2K |
| J1940 | Injection, furosemide, up to 20 mg | 2,791 | 1,287 | $2K |
| J2790 | Injection, rho d immune globulin, human, full dose, 300 micrograms (1500 i.u.) | 40 | 39 | $2K |
| J2916 | Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | 75 | 56 | $2K |
| 69200 | 42 | 41 | $2K | |
| 88300 | 228 | 199 | $2K | |
| 87149 | 71 | 38 | $2K | |
| 86617 | 128 | 88 | $2K | |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 23 | 12 | $2K |
| A9540 | Technetium tc-99m macroaggregated albumin, diagnostic, per study dose, up to 10 millicuries | 71 | 64 | $2K |
| 87177 | 337 | 316 | $2K | |
| 86757 | 137 | 78 | $2K | |
| 81479 | Unlisted molecular pathology procedure | 82 | 70 | $2K |
| 92567 | 122 | 114 | $2K | |
| 82747 | 119 | 113 | $2K | |
| J9171 | Injection, docetaxel, 1 mg | 16 | 13 | $2K |
| 73600 | 69 | 62 | $2K | |
| 88311 | 263 | 222 | $2K | |
| 87015 | 470 | 386 | $2K | |
| 82397 | 129 | 121 | $2K | |
| A9270 | Non-covered item or service | 30,293 | 8,788 | $2K |
| 74420 | 31 | 28 | $2K | |
| 77417 | 34 | 12 | $2K | |
| 84520 | 1,195 | 1,038 | $2K | |
| 83930 | 432 | 376 | $2K | |
| 83521 | 60 | 42 | $2K | |
| 84134 | 166 | 146 | $2K | |
| 95873 | 70 | 51 | $2K | |
| 82043 | 305 | 280 | $2K | |
| 82731 | 101 | 91 | $2K | |
| J9060 | Injection, cisplatin, powder or solution, 10 mg | 104 | 50 | $2K |
| 86356 | 17 | 12 | $2K | |
| 97035 | 133 | 66 | $1K | |
| 86360 | 36 | 31 | $1K | |
| 87324 | 301 | 269 | $1K | |
| 82805 | 37 | 33 | $1K | |
| 76604 | 13 | 12 | $1K | |
| J8540 | Dexamethasone, oral, 0.25 mg | 2,429 | 2,204 | $1K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | 33 | 30 | $1K |
| 82379 | 89 | 81 | $1K | |
| 86880 | 253 | 151 | $1K | |
| 82525 | 81 | 74 | $1K | |
| 86618 | 138 | 122 | $1K | |
| J2550 | Injection, promethazine hcl, up to 50 mg | 2,438 | 1,825 | $1K |
| 87535 | 29 | 28 | $1K | |
| J9260 | Injection, methotrexate sodium, 50 mg | 345 | 203 | $1K |
| J0290 | Injection, ampicillin sodium, 500 mg | 390 | 214 | $1K |
| 84432 | 107 | 96 | $1K | |
| 90461 | 145 | 133 | $1K | |
| 87116 | 190 | 152 | $1K | |
| 94200 | 325 | 307 | $1K | |
| 84270 | 70 | 58 | $1K | |
| 16020 | 29 | 24 | $985.72 | |
| 30300 | 39 | 38 | $968.26 | |
| 82810 | 77 | 67 | $954.92 | |
| 83986 | 632 | 568 | $946.65 | |
| 80202 | 96 | 48 | $926.36 | |
| 74241 | 16 | 12 | $916.46 | |
| 94667 | 61 | 50 | $884.86 | |
| 69210 | 12 | 12 | $807.89 | |
| 87206 | 203 | 164 | $740.10 | |
| J1020 | Injection, methylprednisolone acetate, 20 mg | 311 | 274 | $729.84 |
| 86592 | 217 | 178 | $727.44 | |
| 80175 | 66 | 50 | $701.07 | |
| 81241 | 13 | 13 | $692.80 | |
| 72202 | 12 | 12 | $638.60 | |
| 83498 | 34 | 26 | $633.08 | |
| 84681 | 18 | 16 | $619.53 | |
| 82657 | 28 | 27 | $618.62 | |
| 82542 | 29 | 24 | $618.39 | |
| J1720 | Injection, hydrocortisone sodium succinate, up to 100 mg | 75 | 62 | $593.93 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 948 | 760 | $592.44 |
| 84479 | 89 | 82 | $555.66 | |
| 85303 | 52 | 50 | $544.18 | |
| 85306 | 44 | 41 | $542.12 | |
| 0031A | 16 | 14 | $501.60 | |
| 64495 | 12 | 12 | $496.47 | |
| 99151 | 30 | 30 | $489.64 | |
| 99195 | 21 | 13 | $488.00 | |
| 82365 | 57 | 52 | $474.89 | |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | 341 | 269 | $454.31 |
| 86644 | 18 | 16 | $453.06 | |
| 73020 | 14 | 12 | $419.52 | |
| J0692 | Injection, cefepime hydrochloride, 500 mg | 174 | 54 | $410.87 |
| J1790 | Injection, droperidol, up to 5 mg | 321 | 283 | $391.03 |
| 86762 | 86 | 80 | $390.86 | |
| 82652 | 13 | 13 | $380.24 | |
| 83020 | 29 | 26 | $370.64 | |
| 85300 | 45 | 43 | $356.68 | |
| 70160 | 12 | 12 | $338.10 | |
| 86359 | 16 | 12 | $336.40 | |
| 86355 | 16 | 12 | $336.40 | |
| J1630 | Injection, haloperidol, up to 5 mg | 514 | 420 | $294.45 |
| 84402 | 17 | 13 | $286.52 | |
| 84207 | 12 | 12 | $285.78 | |
| 82232 | 30 | 26 | $275.06 | |
| 82627 | 20 | 13 | $273.42 | |
| 82139 | 17 | 15 | $265.86 | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 19 | 16 | $263.41 |
| 82950 | 30 | 28 | $246.95 | |
| J3360 | Injection, diazepam, up to 5 mg | 17 | 16 | $225.08 |
| 84075 | 34 | 31 | $216.05 | |
| J1250 | Injection, dobutamine hydrochloride, per 250 mg | 75 | 71 | $215.00 |
| 86021 | 17 | 16 | $208.45 | |
| 0279U | 29 | 28 | $207.54 | |
| 85250 | 14 | 14 | $206.58 | |
| 71010 | 16 | 12 | $195.64 | |
| 84155 | 16 | 13 | $188.86 | |
| J2210 | Injection, methylergonovine maleate, up to 0.2 mg | 12 | 12 | $174.09 |
| 86225 | 21 | 12 | $167.49 | |
| 80183 | 14 | 13 | $153.22 | |
| 86300 | 12 | 12 | $142.55 | |
| 85670 | 33 | 29 | $133.00 | |
| 80178 | 33 | 25 | $121.03 | |
| 87425 | 16 | 16 | $119.80 | |
| J0744 | Injection, ciprofloxacin for intravenous infusion, 200 mg | 146 | 68 | $116.81 |
| 86705 | 26 | 26 | $112.34 | |
| 84300 | 39 | 35 | $111.32 | |
| J2800 | Injection, methocarbamol, up to 10 ml | 29 | 26 | $92.54 |
| 84630 | 13 | 12 | $91.12 | |
| J9250 | Methotrexate sodium, 5 mg | 32 | 25 | $90.93 |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | 110 | 108 | $80.57 |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | 331 | 288 | $71.64 |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 20 | 13 | $69.51 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 1,113 | 701 | $58.67 |
| 90685 | 17 | 16 | $54.64 | |
| 84133 | 13 | 12 | $28.38 | |
| J0280 | Injection, aminophyllin, up to 250 mg | 13 | 12 | $20.58 |
| G8984 | Carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals | 269 | 215 | $15.81 |
| G8996 | Swallowing functional limitation, current status at therapy episode outset and at reporting intervals | 109 | 76 | $12.00 |
| J3105 | Injection, terbutaline sulfate, up to 1 mg | 28 | 26 | $9.32 |
| C8937 | Computer-aided detection, including computer algorithm analysis of breast mri image data for lesion detection/characterization, pharmacokinetic analysis, with further physician review for interpretation (list separately in addition to code for primary procedure) | 16 | 15 | $1.17 |
| G8985 | Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 308 | 234 | $1.00 |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | 16 | 16 | $0.13 |
| Q0243 | Injection, casirivimab and imdevimab, 2400 mg | 16 | 12 | $0.01 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 1,017 | 737 | $0.00 |
| G8997 | Swallowing functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 114 | 79 | $0.00 |
| G8981 | Changing & maintaining body position functional limitation, current status, at therapy episode outset and at reporting intervals | 188 | 165 | $0.00 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 354 | 266 | $0.00 |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | 68 | 41 | $0.00 |
| G8982 | Changing & maintaining body position functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 205 | 189 | $0.00 |
| G8998 | Swallowing functional limitation, discharge status, at discharge from therapy or to end reporting | 53 | 43 | $0.00 |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 55 | 29 | $0.00 |